Feliciano Yu · Frontiers in Psychiatry 2026 · descriptive cross-sectional registry study · n=5,935

Inaugural year of regulated psilocybin services in Oregon: safety, motivations, and utilization

Cited 4 times in the scientific literature.

Level 4 - case-series / case-control

Descriptive analysis of statewide aggregate administrative data

OpenAlex W7161045271 · doi:10.3389/fpsyt.2026.1777387 · record verified 2026-08-28

What was done

Descriptive analysis of statewide aggregate data from the Oregon Psilocybin Services (OPS) Public Dashboard covering the inaugural operational year (January 1 to December 31, 2025). The study evaluated total service volume, client demographics, out-of-state participation, and acute adverse events.

What was found

A total of 5,935 clients engaged in 5,375 sessions in 2025, with session counts peaking in Q2 (n = 1,758) and stabilizing in Q4 (n = 1,358). Non-Oregon residents comprised 32.6% of participants. The cohort was predominantly aged 35–49 (~40%), female (57.4%), and included notable LGBTQ+ participation (27.2%). Participants were overwhelmingly White (84.1%–91.5% quarterly), with low participation from Hispanic/Latino (7.1%) and African American (2.1%) individuals. Acute adverse events were rare, with annual rates of 2.42 behavioral events and 2.79 medical events per 1,000 sessions.

Why it matters

This paper provides the first population-level safety and utilization metrics for a state-regulated psilocybin framework in the United States, highlighting practical safety feasibility alongside substantial demographic access disparities.

Limits

The study is limited to aggregated administrative dashboard data without individual-level medical or psychological assessments, precluding efficacy evaluations, baseline diagnostic verification, or longitudinal follow-up. Adverse event rates rely on self- or facilitator-reported registry data, which may be subject to underreporting.

Cited by